DSIP (Delta Sleep-Inducing Peptide): The Sleep Peptide With More Questions Than Answers

DSIP is a small neuropeptide, just nine amino acids long, that was discovered in the 1970s when researchers found a substance in the blood of sleeping rabbits that seemed to induce deep, slow-wave (delta) sleep in other animals. The name promises a lot. The science delivers much less: half a century later, whether DSIP actually helps humans sleep is still genuinely unresolved, and one widely cited review literally called it "a still unresolved riddle."

This guide is the honest, high-level map of the whole compound, and the honesty is the point. We cover what DSIP is and where it came from, what it might do (and why "might" is the right word), the aging evidence on sleep, the other roles it has been studied for, the doses people report, the safety picture, and its research-only legal status. Deep dives that would cannibalize future articles (receptor pharmacology, full protocols, comparisons with other sleep aids) stay as short mini-sections with links out, so this page reads as a clean hub. The one takeaway before the details: DSIP is interesting, under-studied, and unproven, and that combination is exactly why it generates more questions than answers. It also shows up in the focus crowd, where some people chasing the best peptides for focus and cognition reach for it hoping better sleep will clear next-day brain fog.

Key Takeaways

• DSIP (delta sleep-inducing peptide) is a naturally occurring 9-amino-acid neuropeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits during induced sleep, with its structure determined in the late 1970s (Wikipedia, "Delta-sleep-inducing peptide", retrieved 2026-06-15).
• Despite the name, its role in human sleep is not established. A 2006 review in the Journal of Neurochemistry concluded the peptide's link to sleep had never been properly characterized, calling DSIP "a still unresolved riddle" (Kovalzon & Strekalova, J Neurochem, 2006).
• The human clinical evidence is old, small, and weak. A 1992 double-blind study in chronic insomniacs found short-term DSIP unlikely to be of major therapeutic benefit, with effects near placebo (Bes et al., Neuropsychobiology, 1992).
• It has been studied for more than sleep, including stress limitation, pain, and alcohol or opioid withdrawal, again mostly in older, small, animal-heavy work (Graf & Kastin, Peptides, retrieved 2026-06-15).
• It is not FDA-approved and is sold research-use-only. There is no validated human protocol; reported community doses cluster around 100-300 mcg subcutaneously before bed, which is a community convention, not validated dosing.
• It clears the body fast. DSIP has a very short measured half-life, on the order of about 15 minutes in vitro, which complicates any simple "take it and sleep all night" expectation (Wikipedia, "Delta-sleep-inducing peptide", retrieved 2026-06-15).

What is DSIP?

DSIP (delta sleep-inducing peptide) is a small, naturally occurring neuropeptide built from nine amino acids, named for the slow brain waves it was first associated with rather than for any proven effect. It is found in the brain and other tissues across many species, including humans. It is studied mostly in the context of sleep, but its actual biological job is still poorly understood.

In plain terms, DSIP is a tiny protein fragment that the body makes on its own, unlike many research peptides that are purely synthetic inventions. Its amino-acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, and chemically it has the molecular formula C35H48N10O15 with a molecular weight of about 849 g/mol (PubChem, "Delta Sleep-Inducing Peptide, CID 68816", retrieved 2026-06-15). The "delta" in the name refers to delta waves, the large, slow electrical waves the brain produces during the deepest stage of non-REM sleep. If injectable peptides are new to you, start with our what are peptides and how peptides work guides.

The single most important framing for the rest of this guide is this: DSIP is a natural molecule with a famous name and a thin résumé. It is not approved by any drug regulator for any use, the version sold online is an unapproved research chemical, and the evidence that it does what its name implies is genuinely unsettled.

Citation capsule. DSIP (delta sleep-inducing peptide) is a naturally occurring 9-amino-acid neuropeptide, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular formula C35H48N10O15, molecular weight approximately 849 g/mol. It is named for delta-wave (deep) sleep, occurs across many species including humans, and is not approved by any regulator for human use. Source: PubChem CID 68816; Wikipedia, "Delta-sleep-inducing peptide," 2026; CAS reported as 62568-57-4.

Where did DSIP come from?

DSIP was discovered in the 1970s by Swiss researchers who found a sleep-promoting substance in the blood of rabbits whose brains were being electrically stimulated into sleep, then isolated and sequenced it as a nine-amino-acid peptide. This origin story is unusual and is a big part of why the peptide carries such an evocative name.

The work came out of the laboratory of Marcel Monnier and Guido Schoenenberger in Basel. They induced sleep in rabbits by electrically stimulating a sleep-related brain region, then collected blood from the brain's venous drainage and found that transferring it to other animals seemed to promote slow-wave sleep. The active factor was isolated in 1974, and its nine-amino-acid sequence was determined and the peptide synthesized in 1977, published the following year (Schoenenberger et al., Pflügers Archiv, 1978, retrieved 2026-06-15). A common myth worth correcting is that DSIP was "isolated from rats in 1977": it came from rabbits, the isolation was 1974, and 1977 is the year the structure was nailed down.

Here is the honest catch with that origin: a dramatic discovery does not equal a proven drug. The finding was striking enough to earn DSIP its name and decades of curiosity, but isolating a sleep-correlated peptide in animals in the 1970s is the beginning of a research story, not the end of one. As later sections show, the follow-through never produced the clean human result the name implies.

What does DSIP do (or might it do)?

DSIP is proposed to nudge the brain toward deeper, slow-wave sleep and to help the body buffer stress, but no single, well-established mechanism explains how, and the effects reported in studies have been inconsistent. It does not appear to act like a sedative that knocks you out; the proposed picture is more of a subtle modulator.

In simple terms, DSIP is thought to interact with the brain's own sleep-regulating and stress-regulating systems rather than forcing sleep directly. Researchers have reported a grab-bag of possible actions over the years, but importantly, these come mostly from older animal and cell studies and have not converged into one accepted mechanism. The most honest summary is that DSIP looks like a signaling molecule the body uses, and we still do not really know what its main message is.

A hub-level overview of the actions DSIP has been proposed to have, and how solid each is:

• Slow-wave sleep modulation: the headline proposed action, gently shifting brain activity toward delta sleep; reported inconsistently across studies.
• Stress and hormone regulation: proposed to limit stress responses and influence hormones such as corticotropin and somatostatin, mostly in older animal work (Graf & Kastin, Peptides, retrieved 2026-06-15).
• Antioxidant and anticonvulsant effects: reported in some preclinical models, again not confirmed in humans (Wikipedia, "Delta-sleep-inducing peptide", retrieved 2026-06-15).
• A very short stay in the body: DSIP is broken down quickly, with a measured half-life on the order of about 15 minutes in vitro, so any effect is not from the peptide lingering for hours.

The receptor-level deep dive (which exact pathways, whether a dedicated DSIP receptor even exists) is genuinely unsettled and is its own future topic. We keep it at overview level here and point to the how peptides work foundations guide for the basics.

Does DSIP actually help you sleep?

There is no good evidence that DSIP reliably helps humans sleep; the studies are decades old, small, and contradictory, and modern reviews treat the sleep claim as unproven. This is the central honesty of the whole topic: a peptide literally named for sleep does not have the clean human sleep data you would expect.

The clearest verdict comes from a 2006 review in the Journal of Neurochemistry, which revisited three decades of DSIP work and concluded that the peptide's relationship to sleep had never actually been characterized, summing it up in its title as "a still unresolved riddle" (Kovalzon & Strekalova, J Neurochem, 2006, retrieved 2026-06-15). On the clinical side, one of the better human tests was a 1992 double-blind study of chronic insomniacs, which reported that short-term DSIP was "not likely to be of major therapeutic benefit," with effects that did not clearly separate from placebo (Bes et al., Neuropsychobiology, 1992, retrieved 2026-06-15).

Why the sleep evidence is so weak

It helps to understand why a famous "sleep peptide" ended up with such a thin file. First, the strongest claims date to the 1970s and 1980s, an era of small studies and methods that would not meet modern standards, and the results were inconsistent from the start, with some labs unable to reproduce the sleep effect. Second, DSIP is cleared from the body in minutes, which makes it hard to imagine it carrying a person through a full night of sleep on its own, and complicates dosing studies. Third, almost no large, modern, well-controlled human trial has been done, so there is simply no high-quality dataset to settle the question. Newer work does exist, but it tends to be in animals; a 2024 paper in Frontiers in Pharmacology, for example, tested an engineered DSIP fusion peptide in a chemically induced insomnia mouse model rather than in people (Frontiers in Pharmacology, 2024, retrieved 2026-06-15).

The practical translation: anyone selling DSIP as a reliable sleep aid is getting ahead of the science. It might do something for some people, the anecdotes exist, but "the body makes a peptide called delta sleep-inducing peptide" is not the same as "this injection will fix your insomnia." Treat any personal result as an experiment with an unproven tool.

Our take: The name does almost all the marketing here, and that is the trap. "Delta sleep-inducing peptide" sounds like a verdict; it is actually just a label from a 1970s observation that later research could not pin down. When the best review on a compound calls it a "riddle," that is your cue to keep expectations low.

What else has DSIP been studied for?

Beyond sleep, DSIP has been studied for stress resilience, pain, alcohol and opioid withdrawal, and antioxidant effects, but this research is largely old, small, and preclinical, so none of it amounts to a proven human use. These adjacent uses are why DSIP sometimes appears in stress, recovery, or longevity conversations.

The broadest summary of these other roles comes from review work describing DSIP as a multifunctional peptide that interacts with stress hormones and physiological regulation, including effects on corticotropin and somatostatin, blood pressure, and pain perception in animal models (Graf & Kastin, Peptides, retrieved 2026-06-15). In the 1980s, some clinics and researchers also explored DSIP for easing alcohol and opioid withdrawal symptoms, and separately for chronic pain, but those studies were small and have not been confirmed by modern trials.

A quick overview of the non-sleep directions DSIP has been studied for, and where the evidence stands:

Because each of these is a distinct potential future topic, we keep them brief here. The honest headline mirrors the sleep story: DSIP is a peptide that has been tried for many things and proven for none.

What doses of DSIP do people report using?

There is no validated or approved dose of DSIP, but reported community and research-vendor protocols cluster around 100 to 300 mcg injected subcutaneously, taken roughly 30 to 60 minutes before bed, in short cycles. These are figures people report, not an established or recommended dose, and there is no label or approved protocol to anchor them.

The most commonly cited community range is about 100-300 mcg subcutaneously before sleep, with some write-ups mentioning up to 500 mcg, and short-term use rather than continuous daily dosing (Swolverine, "DSIP: Benefits, Dosage and Risks Explained", retrieved 2026-06-15). It is worth stressing how shaky this is: consumer health resources note plainly that there is no standard human protocol for DSIP, and the doses used in actual research were given intravenously in laboratory settings, not as the at-home subcutaneous bedtime shots the community describes (Innerbody, "DSIP", retrieved 2026-06-15). We label every figure here as a community convention because no regulator has reviewed a dose and the human pharmacokinetics are barely studied.

The timing logic is also worth understanding skeptically. Because DSIP is cleared in minutes, users inject shortly before bed hoping to catch sleep onset, but that same fast clearance is why a "lasts all night" claim is hard to credit. For orientation only (not a recommendation):

The detailed reconstitution math, draw volumes, and storage handling are a general process rather than a DSIP-specific science, so we keep them out of this hub and point to the peptide injections guide and getting started with peptides instead.

Our take: The gap between how DSIP was studied (IV, in a lab, in tiny numbers) and how it is used today (subcutaneous, at home, before bed) is huge, and it is rarely acknowledged in the vendor copy. When the studied route and the used route do not even match, "reported dose" is doing a lot of heavy lifting. Treat these numbers as folklore, not a protocol.

What are the side effects of DSIP?

Because DSIP has barely been studied in modern humans, its true side-effect profile is unknown; the limited reports describe mostly mild, short-lived effects, but "unknown" is the honest headline rather than "safe." A naturally occurring peptide is not automatically harmless, especially when injected at non-physiological doses from unregulated sources.

In the small older studies, DSIP was generally described as well tolerated, without dramatic adverse events, which is part of why interest persisted. But that reassurance comes from a thin and dated dataset, and consumer health sources are clear that there is no comprehensive modern safety evaluation in humans (Innerbody, "DSIP", retrieved 2026-06-15). A hub-level overview of what is reported and what remains unknown:

• Commonly reported (mild, anecdotal): injection-site reactions, headache, grogginess or dizziness, and occasional changes in dreams.
• Quality-related risks: because the market is unregulated, contamination, mislabeled potency, or impurities are real concerns independent of the peptide itself.
• Interactions: combining an unproven sleep-active peptide with sedatives, alcohol, or other sleep medications is poorly understood and potentially risky.
• Unknown: true long-term safety in humans, because the long-horizon data simply do not exist.

This is the hub-level summary, not a safety clearance. The absence of reported harm in a handful of small, old studies is not the same as a demonstrated safety record, and an unapproved injectable always carries the added, separate risk of whatever is actually in the vial.

How does DSIP compare to melatonin and other sleep aids?

DSIP is an injectable, unapproved, and unproven research peptide, which puts it in a very different category from melatonin or prescription sleep medications that are regulated, oral, and backed by far more evidence. People reach for DSIP hoping for something "natural and advanced," but on the evidence it is the least proven option, not the most.

The simplest way to hold the contrast is by how much we actually know. Melatonin is an over-the-counter hormone with extensive human data on sleep timing, taken as a pill; prescription sleep medications are FDA-reviewed with known (if imperfect) risk profiles. DSIP, by comparison, is injected, not approved for anything, and rests on the unsettled evidence above. If the question is "what has the strongest case behind it," DSIP is not the answer; its appeal is novelty and the suggestive name, not a superior track record. That is the hub-level contrast, kept brief to avoid overlapping a future dedicated comparison.

Is DSIP safe and legal?

DSIP is not approved by any regulator, so there is no official safety determination, and it cannot be legally sold or prescribed as an approved medicine or included in dietary supplements; the products sold online are unapproved "research chemicals." That status matters more than any single study.

On safety, the older data look unremarkable for an investigational compound, but "unremarkable in small 1980s studies" is not the same as "established safe," and no modern human safety evaluation exists (Innerbody, "DSIP", retrieved 2026-06-15). On legality, the U.S. picture is that DSIP is an unapproved drug: it is not approved by the FDA for any use, it is not a lawful dietary ingredient, and it is sold only labeled "for research use only, not for human consumption." It is generally not a federally scheduled controlled substance, which is sometimes misread as "legal to use," but being un-scheduled is not the same as being approved or safe to take.

Athletes and service members should also be cautious. DSIP is not called out by name on the current World Anti-Doping Agency Prohibited List as of this writing, but WADA's catch-all S0 category covers substances not approved for human therapeutic use, which can sweep in research peptides, and the list is revised annually, so the status should be checked against the current-year list before any competition use. For the full legal picture and how to evaluate a vendor, see the research-chemical legal status guide and how to vet peptide quality (COA, purity, testing).

Our take: "Natural" and "not a controlled substance" get used as reassurance, but neither means what people hope. DSIP being a molecule your body already makes does not make an unregulated injection of it safe, and not being scheduled does not make it approved. Easy to buy is not the same as proven, legal to use, or safe.

How do people obtain DSIP?

Because DSIP is unapproved, people mainly access it by buying unapproved "research chemical" vials of lyophilized powder online, which is a legal and safety gray market, and there is no legitimate prescription route for it outside of a research setting. This is the same gray market that surrounds most research peptides.

Vendors sell DSIP "for research use only," and buyers reconstitute and use it off-label. That market carries real risks of mislabeled potency, impurities, and non-sterile product, with no regulatory oversight of what is actually in the vial. If you are researching that path despite the risks, the responsible groundwork is the same as for any research peptide:

1. Confirm the legal status for your country and situation, including sport and workplace rules. See are peptides legal.
2. Demand a certificate of analysis (COA) from independent third-party testing, and learn to read it for identity and purity. See how to vet peptide quality.
3. Understand handling before anything else. Reconstitution and cold storage are not optional. See getting started with peptides and the peptide injections guide.
4. Talk to a qualified clinician who can weigh your specific health situation, sleep problem, interactions, and contraindications, especially given that proven sleep treatments exist.

We are describing what people do, not endorsing it. Using an unapproved drug for an unproven purpose means accepting unknown risks with no regulatory safety net, and for sleep specifically there are evidence-backed approaches worth exhausting first.

A realistic look at expectations

Going in calibrated matters more for DSIP than for almost any peptide, because the name sets an expectation the evidence cannot meet. Realistic expectations here are genuinely modest and skeptical.

Two honest caveats sit on top of the hype. First, the sleep claim is unproven, so any benefit you notice could be a real effect, a placebo response, or simply normal night-to-night variation, and there is no reliable way to tell them apart without controlled testing. Second, sleep is highly responsive to behavior and environment, so improvements people attribute to DSIP often overlap with better sleep timing, reduced screen use, or regression to the mean. For grounded context on reading transformation and "it worked for me" claims, see peptides before and after.

Frequently Asked Questions

The bottom line

DSIP is one of the most intriguing names in the peptide world and one of the least substantiated stories behind it. The discovery is genuinely fascinating: a sleep-promoting factor pulled from the blood of sleeping rabbits in the 1970s, isolated and sequenced into a tidy nine-amino-acid peptide. That origin, plus the evocative name, is why DSIP keeps resurfacing in sleep and recovery conversations decades later.

The other half of the story is restraint. The human sleep evidence is old, small, and contradictory enough that the definitive review called DSIP "a still unresolved riddle"; the other proposed uses are even thinner; it clears the body in minutes; and it remains an unapproved research chemical with no validated dose and no modern safety evaluation. The honest label is investigational and unproven. If you take one thing from this hub, let it be that a compelling name is not evidence, and that for something as treatable as poor sleep, the proven, regulated options deserve the first look. From here, the natural next reads are how to vet peptide quality, are peptides legal, and getting started with peptides.

Sources

• Wikipedia. "Delta-sleep-inducing peptide." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Delta-sleep-inducing_peptide
• PubChem. "Delta Sleep-Inducing Peptide, CID 68816." National Library of Medicine. Retrieved 2026-06-15. https://pubchem.ncbi.nlm.nih.gov/compound/68816
• Schoenenberger GA, et al. "The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide." Pflügers Archiv, 1978. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/568769/
• Kovalzon VM, Strekalova TV. "Delta sleep-inducing peptide (DSIP): a still unresolved riddle." Journal of Neurochemistry, 2006. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/16539679/
• Bes F, et al. "Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study." Neuropsychobiology, 1992. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/1299794/
• Graf MV, Kastin AJ. "Delta-sleep-inducing peptide (DSIP): characterization, properties and functions." Peptides. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/6548966/
• "A DSIP-fusion peptide for insomnia (PCPA-induced model)." Frontiers in Pharmacology, 2024. Retrieved 2026-06-15. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1439536/full
• Innerbody Research. "DSIP (Delta Sleep-Inducing Peptide): The Full Rundown." Retrieved 2026-06-15. https://www.innerbody.com/dsip-delta-sleep-inducing-peptide
• Swolverine. "DSIP (Delta Sleep-Inducing Peptide): Benefits, Dosage and Risks Explained." Retrieved 2026-06-15. https://swolverine.com/blogs/blog/dsip-delta-sleep-inducing-peptide-benefits-dosage-and-risks-explained